EXSCIENTIA LIMITED

13483814
Active London

Activities of other holding companies n.e.c.

501 employees website.com
Life sciences and medical technology Activities of other holding companies n.e.c.Other research and experimental development on natural sciences and engineering
E

EXSCIENTIA LIMITED

13483814

Activities of other holding companies n.e.c.

Founded 29 Jun 2021 Active London, England 501 employees website.com
Life sciences and medical technology Activities of other holding companies n.e.c.Other research and experimental development on natural sciences and engineering

Previous Company Names

EXSCIENTIA PLC 22 Sept 2021 — 16 Dec 2024
EXSCIENTIA LIMITED 18 Aug 2021 — 22 Sept 2021
EXSCIENTIA HOLDINGS LIMITED 29 Jun 2021 — 18 Aug 2021
Accounts Submitted 12 Nov 2025 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 17 Nov 2025 Next due 1 Dec 2026 5 months remaining
Net assets £356M £123M 2023 year on year
Total assets £511M £139M 2023 year on year
Total Liabilities £155M £16M 2023 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

4th Floor South 3 Pancras Square King’S Cross London N1C 4AG England

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for EXSCIENTIA LIMITED (13483814), an active life sciences and medical technology company based in London, England. Incorporated 29 Jun 2021. Activities of other holding companies n.e.c.. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2023
Type full
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Balance Sheet & P&L (2019–2023)

Cash in Bank

£259.46M

Decreased by £145.11M (-36%)

Net Assets

£355.73M

Decreased by £123.15M (-26%)

Total Liabilities

£155.00M

Decreased by £15.77M (-9%)

Turnover

£21.33M

Decreased by £7.71M (-27%)

Employees

501

Increased by 95 (+23%)

Debt Ratio

30%

Increased by 4 (+15%)

Financial History

Revenue, profit, EBITDA and key financial figures

2023
31 Dec Year End
2022
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

10 Allotments 109,014,445 Shares £23627173497.84m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
26 Aug 2021108,690,325£23627173497.21m£217.38m
26 Aug 20218,726£0£0
10 Aug 202177,699£155k£2
10 Aug 20214,848£10k£2
10 Aug 202130,255£61k£2

Officers

Officers

1 active 2 resigned
Status
Ben Roberts TaylorDirectorAmericanUnited Kingdom4910 Aug 2021Active

Shareholders

Shareholders (1)

Recursion Pharmaceuticals, Inc.
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased

Recursion Pharmaceuticals, Inc.

United States Of America

Active
Notified 20 Nov 2024
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent,right To Appoint And Remove Directors

Andrew Lee Hopkins

Ceased 10 Aug 2021

Ceased

Group Structure

Group Structure

EXSCIENTIA LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
21 May 2026OfficersTermination of Nathan Hatfield as director on 15 May 2026
21 May 2026OfficersTermination of Christopher Gibson as director on 15 May 2026
21 May 2026OfficersAppointment of Andrew John Overton as director on 15 May 2026
21 May 2026OfficersAppointment of Kyle Benjamin Nelson as director on 15 May 2026
21 May 2026OfficersTermination of Nathan Ben Hatfield as director on 15 May 2026
21 May 2026 Officers

Termination of Nathan Hatfield as director on 15 May 2026

21 May 2026 Officers

Termination of Christopher Gibson as director on 15 May 2026

21 May 2026 Officers

Appointment of Andrew John Overton as director on 15 May 2026

21 May 2026 Officers

Appointment of Kyle Benjamin Nelson as director on 15 May 2026

21 May 2026 Officers

Termination of Nathan Ben Hatfield as director on 15 May 2026

Recent Activity

Latest Activity

Termination of Nathan Hatfield as director on 15 May 2026

4 weeks ago on 21 May 2026

Termination of Christopher Gibson as director on 15 May 2026

4 weeks ago on 21 May 2026

Appointment of Andrew John Overton as director on 15 May 2026

4 weeks ago on 21 May 2026

Appointment of Kyle Benjamin Nelson as director on 15 May 2026

4 weeks ago on 21 May 2026

Termination of Nathan Ben Hatfield as director on 15 May 2026

4 weeks ago on 21 May 2026